Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intra-Cellular Ther (NQ: ITCI ) 91.29 +0.78 (+0.86%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Intra-Cellular Ther < Previous 1 2 3 4 5 Next > Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% November 05, 2024 Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile. Via Benzinga Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews November 04, 2024 Via Benzinga Earnings Preview For Intra-Cellular Therapies October 29, 2024 Via Benzinga Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings) October 04, 2024 Via Benzinga Expert Ratings For Intra-Cellular Therapies September 06, 2024 Via Benzinga This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday September 06, 2024 Via Benzinga Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' August 07, 2024 Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. Via Investor's Business Daily Topics Earnings Exposures Financial Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings) August 07, 2024 Via Benzinga A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies July 22, 2024 Via Benzinga Where Intra-Cellular Therapies Stands With Analysts June 12, 2024 Via Benzinga Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment August 06, 2024 New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... Via PressReach Exposures Product Safety NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday July 22, 2024 Via Benzinga China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio? June 23, 2024 Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). Via Benzinga Analyst Ratings For Intra-Cellular Therapies May 08, 2024 Via Benzinga The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts April 22, 2024 Via Benzinga Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 June 20, 2024 Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. Via Investor's Business Daily Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday June 18, 2024 Via Benzinga Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study June 18, 2024 Intra-Cellular Therapies reports positive topline results for Study 502 on lumateperone 42 mg as adjunctive therapy for major depressive disorder. FDA application expected in H2 2024. Via Benzinga Exposures Product Safety Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win June 18, 2024 The company hopes to expand its antipsychotic drug to depression treatment. Via Investor's Business Daily The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio May 30, 2024 While it’s comforting to pick the ideas of the masses, these overlooked stocks may offer superior upside potential for the daring. Via InvestorPlace How Is The Market Feeling About Intra-Cellular Therapies? April 19, 2024 Via Benzinga ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace 3 Biotech Stocks With Skyrocketing Potential: April 2024 April 24, 2024 These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. Via InvestorPlace Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review April 19, 2024 The Nasdaq and S&P 500 tumbled below their 50-day lines. Via Investor's Business Daily Topics Stocks Exposures US Equities Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday April 17, 2024 With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Via Benzinga Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session April 16, 2024 Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session April 16, 2024 Via Benzinga Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study April 16, 2024 Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants. Via Benzinga UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday April 16, 2024 U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Climbs to New 52-Week High April 16, 2024 Via Investor Brand Network < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
